Robert J. Winchester, MD

Board Certifications: 
Rheumatology, Internal Medicine
Profile Hero

Overview

Academic Appointments

  • Professor of Medicine
  • Professor of Pathology & Cell Biology
  • Professor of Pediatrics

Dr. Winchester has had a sustained interest in human autoimmunity. His earlier studies defined the molecular importance of rheumatoid factors, other autoantibodies and immune complexes in human disease. Moreover, Dr. Winchester was involved in the early identification and tissue expression of human MHC class II molecules. As importantly, his studies of the polymorphisms of MHC molecules have provided the basis of establishing the link between MHC genotype and susceptibility to autoimmunity. For example in the late 1980's Dr. Winchester and colleagues showed that susceptibility to rheumatoid arthritis was determined by sequences in the b chain of MHC class II molecules.

This observation led to the shared MHC 'epitope' hypothesis which provides a molecular basis for susceptibility to rheumatoid arthritis associated with a region on the MHC molecule involved in both binding of the peptide and interacting with the TCR. This seminal discovery has emphasized the importance of the modern means of HLA typing which involves DNA sequencing of the MHC genes and the theoretical basis for the discovery of antigens that initiate autoimmune disease. In recent years Dr. Winchester has also focused on DNA and peptide sequence analysis of T cell receptor a and b chains in order to define the changes in the TCR repertoire associated with autoimmunity.

Email: rjw8@cumc.columbia.edu

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • HMO
  • Medicare Managed Care
  • POS
  • PPO
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Cornell University Medical College, NY
  • Internship: New York Hospital - Cornell Medical Center
  • Residency: New York Hospital - Cornell Medical Center

Board Certifications

  • Rheumatology
  • Internal Medicine

Research

Grants

ADIPOSE INFLAMMATION IN RHEUMATOID ARTHRITIS (Federal Gov)

Sep 15 2016 - Aug 31 2021

EARLY IMMUNE EVENTS ASSOCIATED WITH VASCULAR INFLAMMATION IN RHEUMATOID ARTHRITIS (Private)

Aug 8 2018 - Aug 7 2020

SIGNIFICANCE OF INTRARENAL T CELLS IN SLE NEPHRITIS (Federal Gov)

Jan 25 2016 - Dec 31 2019

SIGNIFICANCE OF ELEVATIONS OF CERTAIN MEMORY-EFFECTOR T CELL AND INFLAMMATORY MONOCYTE SUBPOPULATIONS IN RHEUMATOID ARTHRITIS FOR THE PRESENCE OF SUBCLINICAL CORONARY ARTERY ATHEROSCLEROSIS (Private)

Nov 1 2014 - Dec 31 2018

PFIZER INDEPENDENT GRANTS FOR LEARNING AND CHANGE-FELLOWSHIP GRANT (Private)

Jul 1 2016 - Jun 30 2018

ERK SIGNALING IN INFLAMMATORY BONE LOSS (Federal Gov)

Jun 1 2008 - Jan 31 2018

ADIPOSE INFLAMMATION AND HLA OBESITY INTERACTIONS IN PSORIATIC ARTHRITIS (Private)

Jul 1 2015 - Jun 30 2017

PREDICTORS OF PROGRESSION OF ATHEROSCLEROSIS IN RA (Private)

Jul 1 2015 - Jun 30 2017

HETEROGENEITY OF DISEASE MECHANISMS IN PSORIATIC ARTHRITIS (Private)

Apr 1 2015 - Mar 31 2017

AN RA IMMUNE SYSTEM DERIVED FROM PATIENT S STEM CELLS (Federal Gov)

Jul 1 2013 - Mar 31 2016

PATHWAYS AND BIOMARKERS OF MYOCARDIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS (Private)

Jul 1 2013 - Jun 30 2015

ADIPOSE TISSUE INFLAMMATION IN RHEUMATOID ARTHRITIS: ASSOCIATIONS WITH DISEASE CHARACTERISTICS, CARDIOMETABOLIC RISK FACTORS, AND ATHEROSCLEROSIS (Private)

Jul 1 2012 - Jun 30 2014

PROTOCOL ITN034AI: A RANDOMIZED, DOUBLE-BLIND, CONTROLLED , PHASE II MULTICENTER TRIAL OF CYLA4IG (ABATACEPT) PLUS CYCLOPHOSPHAMIDE VS. CYCLOPHOSPHAMIDE ALONE IN THE TREATMENT OF LUPUS NEPHRITIS (Federal Gov)

Jan 1 2008 - Apr 30 2014

A NOVEL, EXPLORATORY APPROACH TO DELINEATING THE MECHANISM OF THE INCREASED RISK OF PREECLAMPSIA IN SLE: INTERACTION OF MATERNAL KIR AND FETAL HLA-C GENOTYPES (Private)

Dec 1 2010 - Nov 30 2013

PFIZER"S MEDICAL & ACADEMIC PARTNERSHIP (MAC) RHEUMATOLOGY V ISTING PROFESSORSHIP AWARD (Private)

Aug 10 2010 - Aug 9 2011

MAPPING AUTOIMMUNE PHENOTYPES IN MULTIPLEX FAMILIES (Federal Gov)

Jul 1 2010 - Jun 30 2011